Key result
Dexmedetomidine significantly reduced the occurrence of spontaneous ventricular premature beats (28.5 vs 50.63) and ventricular tachycardia compared to vehicle in rats with ischemic cardiomyopathy.
Why the study?
Persistent myocardial ischemia post-myocardial infarction can cause fatal ventricular arrhythmias, and the effects of dexmedetomidine on arrhythmogenic properties after ischemic cardiomyopathy remained to be investigated.
Does dexmedetomidine reduce ventricular arrhythmias and fibrosis in a rat model of ischemic cardiomyopathy?
Population
48 rats with ischemic cardiomyopathy after LAD ligation
Comparison
Sham vs Sham+BML vs ICM vs ICM+BML vs ICM+Dex vs ICM+Dex+BML
Design
Randomized preclinical animal study
Follow-up
4 weeks
Authors
Loading...
May support anti-arrhythmic effects of dexmedetomidine post-MI in rats; leaves open translation to human trials.
Does dexmedetomidine reduce ventricular arrhythmias and fibrosis in a rat model of ischemic cardiomyopathy?
Absolute Event Rate: 28.5% vs 50.63%
p-value: p=<0.05
Dexmedetomidine reduces ventricular arrhythmias, fibrosis, and inflammation in a rat model of ischemic cardiomyopathy, likely via AMPK phosphorylation and Cx43 upregulation.
Wu et al. (2020) studied Ischemic cardiomyopathy (n=48). Dexmedetomidine vs. Vehicle (saline with 0.1% DMSO) was evaluated on Occurrence of ventricular premature beats (VPBs) over 1 week (p=<0.05). Dexmedetomidine significantly reduced the occurrence of spontaneous ventricular premature beats (28.5 vs 50.63) and ventricular tachycardia compared to vehicle in rats with ischemic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: